Patient must be fasting for 6-8 hours. Perform coagulation profile (INR/PTT) and platelet count. Ensure cessation of anticoagulants/antiplatelets per protocol. Administer prophylactic intravenous antibiotics. Obtain informed consent and establish IV access.
Observe in recovery for 2-4 hours. Monitor for signs of bleeding, perforation, or biliary peritonitis (abdominal pain, fever). Resume oral intake of clear liquids 2 hours post-procedure if stable. Discharge same day with instructions for soft diet and follow-up clinical assessment within 48 hours.
Comprehensive Guide: Endoscopic Ultrasound-Guided Biliary Drainage (EUS-BD) via Hepaticogastrostomy
1. Introduction and Overview
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD), specifically the Hepaticogastrostomy (EUS-HGS) technique, represents a paradigm shift in interventional gastroenterology and hepatobiliary medicine. Traditionally, biliary obstruction was managed via Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiography (PTC). However, when these conventional methods fail—often due to surgically altered anatomy, duodenal obstruction, or inaccessible papillae—EUS-HGS provides a minimally invasive, internal drainage solution.
EUS-HGS involves the creation of a transmural fistula between the left intrahepatic bile duct and the stomach wall under real-time EUS guidance. This allows for the placement of a stent, facilitating the drainage of bile into the stomach, thereby bypassing the obstructed distal bile duct. This guide serves as a clinical resource for practitioners and healthcare professionals involved in the management of complex biliary obstruction.
2. Technical Specifications and Mechanisms
The mechanism of EUS-HGS relies on the anatomical proximity of the left hepatic lobe (specifically segments II and III) to the gastric cardia and fundus.
The Procedural Workflow
The procedure is typically performed using a linear array echoendoscope. The technical steps are as follows:
- Visualization: The echoendoscope is positioned in the stomach to visualize the left intrahepatic bile ducts (LIHBD).
- Puncture: A 19G or 22G fine-needle aspiration (FNA) needle is used to puncture the dilated LIHBD under EUS guidance.
- Cholangiography: Contrast agent is injected to confirm ductal access (fluoroscopic visualization).
- Guidewire Placement: A 0.025-inch or 0.035-inch guidewire is advanced through the needle and coiled within the biliary tree.
- Tract Dilation: The fistula tract is dilated using a small-diameter cystotome, balloon catheter, or specialized dilator.
- Stent Deployment: A dedicated biliary stent (usually a Fully Covered Self-Expandable Metal Stent - FCSEMS, or a lumen-apposing metal stent - LAMS) is deployed across the gastric wall into the bile duct.
| Component | Specification/Type |
|---|---|
| Echoendoscope | Linear array (e.g., Olympus GF-UCT180) |
| Needle | 19G FNA needle (Standard) |
| Guidewire | 0.025" or 0.035" hydrophilic wire |
| Stent Type | FCSEMS (Biliary) or LAMS |
| Dilation Method | Hydrostatic balloon or electrocautery dilator |
3. Clinical Indications and Usage
EUS-HGS is reserved for patients where ERCP is not feasible or has failed. It is categorized as a "rescue" therapy or an alternative to PTC.
Primary Indications
- Failed ERCP: Anatomy prevents reaching the papilla (e.g., Roux-en-Y gastric bypass, Whipple procedure).
- Malignant Biliary Obstruction: Unresectable pancreatic cancer or cholangiocarcinoma where the distal duct is blocked.
- Benign Biliary Strictures: Chronic pancreatitis or post-surgical strictures refractory to standard endoscopic therapy.
- Duodenal Obstruction: Preventing access to the papilla due to tumor ingrowth.
Patient Selection Criteria
- Ductal Dilation: Intrahepatic duct diameter > 5mm is generally required for safe puncture.
- Anatomical Accessibility: The LIHBD must be accessible via the gastric fundus.
- Performance Status: Patients must be stable enough to undergo moderate to deep sedation.
4. Risks, Side Effects, and Contraindications
Contraindications
- Coagulopathy: Uncorrected INR > 1.5 or platelet count < 50,000/μL.
- Ascites: Presence of significant ascites increases the risk of bile peritonitis.
- Unfavorable Anatomy: Inability to visualize the LIHBD or interposition of blood vessels.
Potential Complications
Despite its efficacy, EUS-HGS is technically demanding. Complications occur in approximately 10–20% of cases:
- Bile Peritonitis: Leakage of bile into the peritoneal cavity if the stent migrates or the tract is not sealed properly.
- Stent Migration: Movement of the stent into the stomach or the biliary tree.
- Bleeding: Hemorrhage from the gastric wall or the liver parenchyma.
- Pneumoperitoneum: Air entry into the peritoneal cavity during the procedure.
- Infection: Cholangitis due to stent occlusion or retrograde seeding.
5. Pre-operative Preparation and Post-operative Protocol
Pre-operative Preparation
- Imaging: Contrast-enhanced CT or MRI/MRCP to map the biliary tree and gastric anatomy.
- Antibiotic Prophylaxis: Broad-spectrum antibiotics (e.g., Ciprofloxacin or Ceftriaxone) should be administered 30 minutes prior to the procedure.
- Coagulation Profile: Review of CBC and coagulation studies; correction if necessary.
- Informed Consent: Detailed discussion regarding the risk of perforation and peritonitis.
Post-operative Protocol
- Monitoring: Vital signs monitored every 4 hours for the first 24 hours.
- Diet: NPO for 6–12 hours, followed by a clear liquid diet if the patient is asymptomatic.
- Imaging: Abdominal X-ray or CT scan within 24 hours to ensure proper stent position and check for pneumoperitoneum.
- Follow-up: Clinical assessment for jaundice resolution and liver function test (LFT) normalization within 1 week.
6. Expected Outcomes
EUS-HGS boasts a high technical success rate, often reported between 90% and 98% in expert centers. Clinical success, defined by the resolution of jaundice and reduction of bilirubin, is typically achieved in 85–90% of patients. Compared to PTC, EUS-HGS is associated with fewer external drainage-related complications and improved patient quality of life, as it avoids the need for an external biliary catheter bag.
7. Frequently Asked Questions (FAQ)
1. How does EUS-HGS differ from traditional ERCP?
ERCP accesses the bile duct through the natural papilla in the duodenum. EUS-HGS bypasses the papilla entirely, accessing the bile duct through the stomach wall.
2. What is the main advantage of EUS-HGS over PTC?
EUS-HGS provides internal drainage, meaning bile drains into the stomach rather than into an external bag, which is more comfortable for the patient and reduces the risk of skin infection.
3. Is general anesthesia required?
Most procedures are performed under deep sedation or monitored anesthesia care (MAC), depending on institutional protocols.
4. What happens if the stent becomes blocked?
If the stent occludes (usually due to sludge or tumor ingrowth), it can often be replaced endoscopically or cleared using a balloon sweep, similar to standard biliary stents.
5. How long does the stent stay in place?
In malignant cases, the stent is often left in place permanently. In benign cases, it may be removed once the underlying stricture has resolved, though this is rare.
6. What are the signs of bile peritonitis post-procedure?
Symptoms include severe abdominal pain, fever, tachycardia, and rebound tenderness. This is a medical emergency requiring immediate imaging and surgical consultation.
7. Can EUS-HGS be performed if the patient has had a Whipple procedure?
Yes, EUS-HGS is frequently used in patients with altered anatomy, including those who have undergone a Whipple procedure, as the papilla is often inaccessible.
8. What is the role of LAMS in EUS-HGS?
Lumen-apposing metal stents (LAMS) are increasingly used because they provide better "anchoring" between the stomach and the bile duct, theoretically reducing the risk of migration and leakage.
9. Is EUS-HGS considered a first-line treatment?
No. It is typically a second or third-line treatment reserved for cases where ERCP has failed or is anatomically impossible.
10. What is the typical duration of the procedure?
In experienced hands, the procedure typically lasts between 45 and 90 minutes.
8. Alternative Treatments
When EUS-HGS is not suitable, clinicians may consider:
* Percutaneous Transhepatic Cholangiography (PTC): The traditional external drainage method.
* EUS-Guided Anterograde Drainage (EUS-AG): If the papilla is accessible but the duct cannot be cannulated retrograde.
* Surgical Biliary Bypass: A more invasive procedure involving a hepaticojejunostomy, typically reserved for patients who are surgical candidates with a long life expectancy.
Conclusion
EUS-HGS is a sophisticated, highly effective intervention for biliary obstruction. Its success is predicated on technical expertise, careful patient selection, and rigorous post-procedural monitoring. As interventional EUS technology continues to evolve, EUS-HGS remains a cornerstone of minimally invasive hepatobiliary care, offering patients a superior alternative to external drainage options.
Disclaimer: This document is for educational purposes for healthcare professionals and does not replace institutional clinical guidelines or professional medical judgment. Always refer to the latest clinical trials and local hospital policies regarding interventional procedures.
